Peroneal Electrical Transcutaneous NeuroModulation as a New Treatment for Patients with Overactive Bladder: An Initial Clinical Experience
- PMID: 35316811
- DOI: 10.1159/000522570
Peroneal Electrical Transcutaneous NeuroModulation as a New Treatment for Patients with Overactive Bladder: An Initial Clinical Experience
Abstract
Introduction: The aim of this study was to determine whether peroneal electrical Transcutaneous NeuroModulation (peroneal eTNM®) using the URIS® neuromodulation system can be used in individuals with refractory overactive bladder (OAB).
Methods: Eighteen female patients with idiopathic OAB who failed previous behavioral and pharmacological therapy were enrolled. Patients were treated with the URIS® neuromodulation system using active electrodes placed on the popliteal fossa, targeting the peroneal nerve for 30 min once a week for 12 weeks. Changes in OAB symptoms and patient-reported outcomes from baseline to the end of the study were analyzed. A nonparametric Wilcoxon signed-rank test was used to assess changes in variables. Statistical significance was defined as p ≤ 0.05.
Results: We observed a significant reduction in micturition frequency (p = 0.022), number of severe urgency episodes (p < 0.001), urgency incontinence episodes (p = 0.001), and nocturia episodes (p = 0.027). A decrease in Patient Perception of Bladder Condition score (p < 0.001) was also observed. Posttreatment, 15 patients (83.3%) reported a moderate or significant reduction in their bladder bother. Throughout the study, two adverse events were recorded with no causal relationship to the study treatment.
Discussion/conclusions: Our study documented a significant reduction in all OAB symptoms and an improvement in all patient-reported outcomes in patients treated with peroneal eTNM® using the URIS® neuromodulation system.
Keywords: Neuromodulation; Overactive bladder; Patient-reported outcomes; Peroneal nerve; Urgency.
© 2022 S. Karger AG, Basel.
Similar articles
-
Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder.Int Urogynecol J. 2023 Jun;34(6):1253-1260. doi: 10.1007/s00192-022-05359-3. Epub 2022 Sep 20. Int Urogynecol J. 2023. PMID: 36125509
-
Effect duration of the initial course of peroneal electrical Transcutaneous NeuroModulation in patients with overactive bladder.World J Urol. 2023 Jun;41(6):1629-1634. doi: 10.1007/s00345-023-04394-z. Epub 2023 Apr 7. World J Urol. 2023. PMID: 37027023
-
Prospective, Randomized, Multicenter Trial of Peroneal Electrical Transcutaneous Neuromodulation vs Solifenacin in Treatment-naïve Patients With Overactive Bladder.J Urol. 2023 Apr;209(4):734-741. doi: 10.1097/JU.0000000000003141. Epub 2022 Dec 29. J Urol. 2023. PMID: 36579932 Clinical Trial.
-
Do we need more patient-friendly treatment options for overactive bladder (OAB)?Neurourol Urodyn. 2021 Aug;40(6):1433-1440. doi: 10.1002/nau.24731. Epub 2021 Jun 21. Neurourol Urodyn. 2021. PMID: 34153139 Free PMC article. Review.
-
[The new era in the pharmacological treatment of overactive bladder (OAB): mirabegron--a new selective beta3agonist].Ginekol Pol. 2014 Mar;85(3):214-9. doi: 10.17772/gp/1716. Ginekol Pol. 2014. PMID: 24783434 Review. Polish.
Cited by
-
Peroneal electrical transcutaneous neuromodulation in the home treatment of the refractory overactive bladder.Int Urogynecol J. 2023 Jun;34(6):1253-1260. doi: 10.1007/s00192-022-05359-3. Epub 2022 Sep 20. Int Urogynecol J. 2023. PMID: 36125509
MeSH terms
LinkOut - more resources
Full Text Sources
Medical